Literature DB >> 31101931

CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor.

Philippe P Pagni1, Anitra Wolf1, Mauro Lo Conte1, Ronald Yeh1, Guangsen Fu1, Fa Liu1, Matthias von Herrath1, Ken Coppieters2.   

Abstract

Entities:  

Keywords:  CD40; CD40L; Type 1 diabetes

Mesh：

Substances：

Year:  2019        PMID： 31101931     DOI： 10.1007/s00125-019-4893-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  6 in total

1.  Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation.

Authors:  Hyun-Jung An; Young Jin Kim; Dong Hyun Song; Beom Suk Park; Ho Min Kim; Ju Dong Lee; Sang-Gi Paik; Jie-Oh Lee; Hayyoung Lee
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

2.  CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells.

Authors:  Dirk Homann; Angelika Jahreis; Tom Wolfe; Anna Hughes; Bryan Coon; Marianne J B van Stipdonk; Kiley R Prilliman; Stephen P Schoenberger; Matthias G von Herrath
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

3.  CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice.

Authors:  B Balasa; T Krahl; G Patstone; J Lee; R Tisch; H O McDevitt; N Sarvetnick
Journal:  J Immunol       Date:  1997-11-01       Impact factor: 5.422

4.  Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice.

Authors:  Liza Robles-Carrillo; Todd Meyer; Meghan Hatfield; Hina Desai; Mónica Dávila; Florian Langer; Mildred Amaya; Ellen Garber; John L Francis; Yen-Ming Hsu; Ali Amirkhosravi
Journal:  J Immunol       Date:  2010-06-28       Impact factor: 5.422

5.  A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice.

Authors:  Gisela M Vaitaitis; Michael H Olmstead; Dan M Waid; Jessica R Carter; David H Wagner
Journal:  Diabetologia       Date:  2014-08-08       Impact factor: 10.122

6.  In silico approaches for predicting the half-life of natural and modified peptides in blood.

Authors:  Deepika Mathur; Sandeep Singh; Ayesha Mehta; Piyush Agrawal; Gajendra P S Raghava
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240
  6 in total
  2 in total

1.  CD40-targeting KGYY15 peptides do not efficiently block the CD40-CD40L interaction.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Diabetologia       Date:  2019-09-09       Impact factor: 10.122

2.  CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor. Reply to Pagni PP, Wolf A, Lo Conte M et al [letter].

Authors:  Gisela M Vaitaitis; Michael H Olmstead; Dan M Waid; Jessica R Carter; David H Wagner
Journal:  Diabetologia       Date:  2019-07-08       Impact factor: 10.122
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.